Pittsburgh Compound B

CAT:
804-HY-126192-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Pittsburgh Compound B - image 1

Pittsburgh Compound B

  • Description:

    Pittsburgh Compound B (PiB) is a PET tracer for Aβ deposition in Alzheimer's disease (AD), with high affinity and specificity. Through click chemistry modification (introducing a PEG3 linker and an alkyne group at the 6-hydroxy position of Pittsburgh Compound B to generate a clickable Pittsburgh Compound B derivative, followed by covalent conjugation with azide-labeled fluorescent dyes or affinity tags via copper-catalyzed azide-alkyne cycloaddition (CuAAC) ), Pittsburgh Compound B and its conjugates can be used for fluorescence imaging, ultrastructural studies, and the enrichment and characterization of Aβ complexes. Pittsburgh Compound B holds great potential in Alzheimer's disease research[1].
  • Product Name Alternative:

    PiB; 6-OH-BTA-1
  • UNSPSC:

    12352005
  • Hazard Statement:

    H302, H315, H319, H332, H335
  • Target:

    Amyloid-β
  • Related Pathways:

    Neuronal Signaling
  • Applications:

    Neuroscience-Neurodegeneration
  • Field of Research:

    Neurological Disease
  • Purity:

    98.0
  • Solubility:

    DMSO : 50 mg/mL (ultrasonic)
  • Smiles:

    OC1=CC=C2N=C (SC2=C1) C3=CC=C (C=C3) NC
  • Molecular Formula:

    C14H12N2OS
  • Molecular Weight:

    256.33
  • Precautions:

    H302, H315, H319, H332, H335
  • References & Citations:

    [1]Diner I, et al. Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain. Bioconjug Chem. 2017 Oct 18;28 (10) :2627-2637.|[2]Diner I, et al. Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain. Bioconjug Chem. 2017 Oct 18;28 (10) :2627-2637.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    4°C (Powder, protect from light, stored under nitrogen)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    Phase 4
  • CAS Number:

    566169-93-5